Search
Lumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnLumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver
Categories: COX-2 Inhibitors, Cytochrome P-450 SubstratesSynonyms: 2-((2-chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acidTadalafil
go.drugbank.com/drugs/DB00820ApprovedInvestigational[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. … In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment
Mixtures: TADA PLUS 30/20 MG FILM KAPLI TABLET ,4 ADET, TADA PLUS 30/20 MG FILM KAPLI TABLET ,8 ADETCategories: 5-alpha Reductase Inhibitors, Cytochrome P-450 SubstratesCarteolol
go.drugbank.com/drugs/DB00521ApprovedA beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingProducts: CARTEOL LP %1 UZUN ETKILI GOZ DAMLASI, 3 ML, CARTEOL LP %2 UZUN ETKILI GOZ DAMLASI, 3 MLEscitalopram
go.drugbank.com/drugs/DB01175ApprovedInvestigationalEscitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. … [L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting
Categories: Monoamine Oxidase A Substrates, P-glycoprotein substratesSynonyms: (S)-Citalopram, S(+)-CitalopramDaunorubicin
go.drugbank.com/drugs/DB00694ApprovedInvestigationalA very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Synonyms: (8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione, Leukaemomycin CCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexNizatidine
go.drugbank.com/drugs/DB00585ApprovedA histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingSynonyms: N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamineAnidulafungin
go.drugbank.com/drugs/DB00362ApprovedThere is preliminary evidence that it has a similar safety profile to caspofungin. … Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366.
Products: GIXOFU 100 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE, FUNİDUL 100 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 1 ADETMebrofenin
go.drugbank.com/drugs/DB15779ApprovedProducts: POLTECHMBRIDA 20 MG. KIT PARA LA PREPARACION RADIOFARMACEUTICAErlotinib
go.drugbank.com/drugs/DB00530ApprovedInvestigationalRecent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion … Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amineChloroquine
go.drugbank.com/drugs/DB00608ApprovedInvestigationalVet approved[A191787] Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis … [A192432] **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Synonyms: N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamineInternational brands: Nivaquine B